ATE354563T1 - Sulfonderivate zur hemmung von gamma-secretase - Google Patents
Sulfonderivate zur hemmung von gamma-secretaseInfo
- Publication number
- ATE354563T1 ATE354563T1 AT03753700T AT03753700T ATE354563T1 AT E354563 T1 ATE354563 T1 AT E354563T1 AT 03753700 T AT03753700 T AT 03753700T AT 03753700 T AT03753700 T AT 03753700T AT E354563 T1 ATE354563 T1 AT E354563T1
- Authority
- AT
- Austria
- Prior art keywords
- gamma secretase
- sulfone derivatives
- inhibiting gamma
- inhibiting
- secretase
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003457 sulfones Chemical class 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Picture Signal Circuits (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0223040.7A GB0223040D0 (en) | 2002-10-04 | 2002-10-04 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE354563T1 true ATE354563T1 (de) | 2007-03-15 |
Family
ID=9945314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03753700T ATE354563T1 (de) | 2002-10-04 | 2003-09-25 | Sulfonderivate zur hemmung von gamma-secretase |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7161006B2 (de) |
| EP (1) | EP1551798B1 (de) |
| JP (1) | JP4478025B2 (de) |
| AT (1) | ATE354563T1 (de) |
| AU (1) | AU2003271862B2 (de) |
| CA (1) | CA2500966A1 (de) |
| DE (1) | DE60312017T2 (de) |
| ES (1) | ES2280785T3 (de) |
| GB (1) | GB0223040D0 (de) |
| WO (1) | WO2004031138A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| JP4329905B2 (ja) | 2001-12-27 | 2009-09-09 | 第一三共株式会社 | βアミロイド蛋白産生・分泌阻害剤 |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| CA2526487A1 (en) | 2003-06-30 | 2005-01-06 | Daiichi Pharmaceutical Co., Ltd. | Heterocyclic methyl sulfone derivative |
| EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| US8133857B2 (en) * | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| US8304434B2 (en) | 2007-10-04 | 2012-11-06 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
| WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2011009064A1 (en) * | 2009-07-17 | 2011-01-20 | The J. David Gladstone Institutes | Methods of controlling cell proliferation |
| BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP2601293B1 (de) | 2010-08-02 | 2017-12-06 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina) |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2013059302A1 (en) | 2011-10-17 | 2013-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| EP2900241B1 (de) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Neuartige verbindungen als erk-hemmer |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| EP2951180B1 (de) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8-substituierte purine als hdm2-inhibitoren |
| EP3041938A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Kreisförmige polynukleotide |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3706742B1 (de) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2020016377A1 (en) | 2018-07-19 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination for treating cancer |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| BR112021002267A8 (pt) | 2018-08-07 | 2023-02-07 | Merck Sharp & Dohme | Inibidores de prmt5 |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP4077282A4 (de) | 2019-12-17 | 2023-11-08 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2021126728A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP4076460B1 (de) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs |
| EP4244391A1 (de) | 2020-11-16 | 2023-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und zusammensetzungen zur vorhersage und behandlung von uvealem melanom |
| PE20251401A1 (es) | 2022-09-02 | 2025-05-22 | Merck Sharp And Dohme Llc | Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos |
| AU2023366166A1 (en) | 2022-10-25 | 2025-05-01 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| EP4633681A1 (de) | 2022-12-14 | 2025-10-22 | Merck Sharp & Dohme LLC | Auristatin-linker-payloads, pharmazeutische zusammensetzungen und verwendungen davon |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20013000A3 (cs) * | 1999-02-26 | 2002-02-13 | Merck & Co., Inc. | Nové sulfonamidové sloučeniny a jejich pouľití |
-
2002
- 2002-10-04 GB GBGB0223040.7A patent/GB0223040D0/en not_active Ceased
-
2003
- 2003-09-25 CA CA002500966A patent/CA2500966A1/en not_active Abandoned
- 2003-09-25 WO PCT/GB2003/004173 patent/WO2004031138A1/en not_active Ceased
- 2003-09-25 AU AU2003271862A patent/AU2003271862B2/en not_active Ceased
- 2003-09-25 EP EP03753700A patent/EP1551798B1/de not_active Expired - Lifetime
- 2003-09-25 JP JP2004540929A patent/JP4478025B2/ja not_active Expired - Lifetime
- 2003-09-25 DE DE60312017T patent/DE60312017T2/de not_active Expired - Lifetime
- 2003-09-25 AT AT03753700T patent/ATE354563T1/de not_active IP Right Cessation
- 2003-09-25 US US10/528,214 patent/US7161006B2/en not_active Expired - Fee Related
- 2003-09-25 ES ES03753700T patent/ES2280785T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2500966A1 (en) | 2004-04-15 |
| DE60312017D1 (de) | 2007-04-05 |
| EP1551798B1 (de) | 2007-02-21 |
| US7161006B2 (en) | 2007-01-09 |
| GB0223040D0 (en) | 2002-11-13 |
| DE60312017T2 (de) | 2007-10-25 |
| JP2006501293A (ja) | 2006-01-12 |
| US20050261276A1 (en) | 2005-11-24 |
| AU2003271862A1 (en) | 2004-04-23 |
| WO2004031138A1 (en) | 2004-04-15 |
| JP4478025B2 (ja) | 2010-06-09 |
| EP1551798A1 (de) | 2005-07-13 |
| ES2280785T3 (es) | 2007-09-16 |
| AU2003271862B2 (en) | 2009-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE354563T1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| ATE386028T1 (de) | Zyklohexylsulfone als gamma-sekretase-inhibitoren | |
| DE60329533D1 (de) | Cyclische sulfamide zur inhibierung von gamma-sekretase | |
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
| DE60112957D1 (de) | Sulfamide als gamma-secretase-inhibitoren | |
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| ATE416761T1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| ATE427300T1 (de) | Heterocyclisch substituierte amide als calpainhemmer | |
| WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE414089T1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| DE60221627D1 (de) | Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren | |
| WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE60237725D1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| DE602004011255D1 (de) | Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| NO20054744L (no) | Behandling av Alzheimers sykdom | |
| ATE469886T1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
| ATE530525T1 (de) | Piperidine und verwandte verbindungen zur behandlung von demenz | |
| ATE556053T1 (de) | Piperidinderivate zur behandlung von alzheimer- krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |